Literature DB >> 24290360

MUC2 expression is an adverse prognostic factor in superficial gastroesophageal adenocarcinomas.

Jon M Davison1, Shane T Ellis2, Tyler J Foxwell3, James D Luketich4, Michael K Gibson2, Shih-Fan Kuan3, Katie S Nason4.   

Abstract

Mucin core proteins (MUCs) are expressed in tissue-specific patterns in the gastrointestinal tract and expression is deregulated in Barrett's metaplasia. Based on differential expression, MUCs have been used to classify adenocarcinomas into distinct phenotypes (eg, intestinal, gastric, pancreaticobiliary, etc). Because MUC expression patterns carry prognostic significance in other tumors, we evaluated MUC expression in superficial adenocarcinomas of the gastroesophageal junction and esophagus (EAC) to determine whether there are differences in outcome associated with MUC subtype in this potentially curable subset of EAC. We classified 142 resected, superficial (T1) EAC based on their pattern of expression of MUC2, MUC5AC, MUC6 and MUC1. The association between survival and MUC expression pattern was determined in univariate and multivariate analyses. The MUC2 positive "intestinal" phenotype was associated with significantly worse prognosis in submucosal EAC (hazard ratio 2.2, 95% confidence interval 1.2-4.2), independent of node stage and other prognostic factors. MUC2 expression in submucosal EAC also showed significantly accelerated time to recurrence (hazard ratio 2.8, 95% confidence interval 1.2-6.8) after adjusting for node stage. The classification of superficial EAC by MUC protein expression has prognostic significance. MUC2 expression is an adverse prognostic indicator in submucosal EAC, independent of node stage and other prognostic factors.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Esophagus; Glandular and epithelial neoplasms; MUC2 protein; Mucins; Survival

Mesh:

Substances:

Year:  2013        PMID: 24290360      PMCID: PMC3935247          DOI: 10.1016/j.humpath.2013.10.020

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  31 in total

1.  Mucin core proteins as differentiation markers in the gastrointestinal tract.

Authors:  J R Jass
Journal:  Histopathology       Date:  2000-12       Impact factor: 5.087

2.  [Neoadjuvant intra-arterial chemotherapy based on chemosensitivity tests for locally invasive bladder cancer].

Authors:  M Ogihara; K Aikawa; K Ishibashi; O Yamaguchi; Y Shiraiwa; K Koseki
Journal:  Hinyokika Kiyo       Date:  1997-08

3.  Differential expression of mucin genes in mammary and extramammary Paget's disease.

Authors:  S F Kuan; A G Montag; J Hart; T Krausz; W Recant
Journal:  Am J Surg Pathol       Date:  2001-12       Impact factor: 6.394

4.  Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary.

Authors:  C Hanski; M Hofmeier; A Schmitt-Gräff; E Riede; M L Hanski; F Borchard; E Sieber; F Niedobitek; H D Foss; H Stein; E O Riecken
Journal:  J Pathol       Date:  1997-08       Impact factor: 7.996

5.  Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status.

Authors:  Mohamad A Eloubeidi; Renee Desmond; Miguel R Arguedas; Carolyn E Reed; C Mel Wilcox
Journal:  Cancer       Date:  2002-10-01       Impact factor: 6.860

6.  Re-evaluation of mucin phenotypes of gastric minute well-differentiated-type adenocarcinomas using a series of HGM, MUC5AC, MUC6, M-GGMC, MUC2 and CD10 stains.

Authors:  Hidefumi Shiroshita; Hidenobu Watanabe; Yoichi Ajioka; Gen Watanabe; Ken Nishikura; Seigo Kitano
Journal:  Pathol Int       Date:  2004-05       Impact factor: 2.534

7.  Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors.

Authors:  K S McCarty; E Szabo; J L Flowers; E B Cox; G S Leight; L Miller; J Konrath; J T Soper; D A Budwit; W T Creasman
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

8.  Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach.

Authors:  U Flucke; E Steinborn; V Dries; S P Mönig; P M Schneider; J Thiele; A H Hölscher; H P Dienes; S E Baldus
Journal:  Histopathology       Date:  2003-08       Impact factor: 5.087

9.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

10.  Human MUC2 mucin gene is transcriptionally regulated by Cdx homeodomain proteins in gastrointestinal carcinoma cell lines.

Authors:  Patrícia Mesquita; Nicolas Jonckheere; Raquel Almeida; Marie-Paule Ducourouble; Jacinta Serpa; Elisabete Silva; Pascal Pigny; Filipe Santos Silva; Celso Reis; Debra Silberg; Isabelle Van Seuningen; Leonor David
Journal:  J Biol Chem       Date:  2003-10-02       Impact factor: 5.157

View more
  6 in total

1.  The revised American Joint Committee on Cancer staging system (7th edition) improves prognostic stratification after minimally invasive esophagectomy for esophagogastric adenocarcinoma.

Authors:  Haris Zahoor; James D Luketich; Benny Weksler; Daniel G Winger; Neil A Christie; Ryan M Levy; Michael K Gibson; Jon M Davison; Katie S Nason
Journal:  Am J Surg       Date:  2015-06-26       Impact factor: 2.565

2.  Effects of estrogen on esophageal function through regulation of Ca2+-related proteins.

Authors:  Kipung Kim; Dongoh Lee; Changhwan Ahn; Hee Young Kang; Beum-Soo An; Yeon Hee Seong; Eui-Bae Jeung
Journal:  J Gastroenterol       Date:  2017-01-11       Impact factor: 7.527

3.  Construction and analysis of three networks of genes and microRNAs in adenocarcinoma.

Authors:  Jiahui Ning; Xiaoxin Guo; Ning Wang; Luchen Xue
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

4.  Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Sarah Derks; Katie S Nason; Jon M Davison; Adam J Bass; Xiaoyun Liao; Matthew D Stachler; Kevin X Liu; Jie Bin Liu; Ewa Sicinska; Michael S Goldberg; Gordon J Freeman; Scott J Rodig
Journal:  Cancer Immunol Res       Date:  2015-06-16       Impact factor: 11.151

Review 5.  Gastric Adenocarcinoma: A Multimodal Approach.

Authors:  Humair S Quadri; Brandon G Smaglo; Shannon J Morales; Anna Chloe Phillips; Aimee D Martin; Walid M Chalhoub; Nadim G Haddad; Keith R Unger; Angela D Levy; Waddah B Al-Refaie
Journal:  Front Surg       Date:  2017-08-03

6.  A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas.

Authors:  Aafke Creemers; Eva A Ebbing; Thomas C Pelgrim; Sjoerd M Lagarde; Faridi S van Etten-Jamaludin; Mark I van Berge Henegouwen; Maarten C C M Hulshof; Kausilia K Krishnadath; Sybren L Meijer; Maarten F Bijlsma; Martijn G H van Oijen; Hanneke W M van Laarhoven
Journal:  Sci Rep       Date:  2018-09-05       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.